NervGen Pharma Corp. (NGENF) Stock Analysis
DELISTED 2026
What happened to NervGen Pharma Corp. (NGENF) stock?
NervGen Pharma Corp. (NGENF) no longer trades on public markets. It was delisted in January 2026. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
- Delisting date:
- January 2026
- Last recorded price (historical):
- $3.95 (last quote on record before the January 2026 delisting; historical, not a current quote)
Market cap $313M is the value of all shares combined.
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
NervGen Pharma Corp. (NGENF). NervGen Pharma Corp. is a biotechnology company focused on developing treatments for nervous system damage, with its lead product candidate, NVG-291, currently in Phase 1 clinical trials.
Last analyzed: Mar 17, 2026NervGen Pharma Corp. (NGENF) Healthcare & Pipeline Overview
NGENF OTC Market Information
NGENF trades on the OTC Other market tier of OTC Markets.
- OTC Tier: OTC Other
More about this archive record
Can I still buy NGENF shares?
No. NGENF stopped trading on public markets in January 2026, so the shares are not available through a broker. Anything you see quoted for NGENF elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before NGENF stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to NervGen Pharma Corp.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.